FDA gives nod to hemophilia kit

09/14/2004 | NYTimes.com

Wyeth Pharmaceuticals won approval for its needle-free kit that reconstitutes factor VIII, an important blood protein that helps form clots. The ReFactor Antihemophilic Factor R2 kit is intended to help patients get regular treatment more quickly and safely for the inherited blood disorder.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD